E-Newsletter - May 2022
Spotlight on Alliance Trials


Two alliance trials now actively Enrolling participants
with recurrent glioblastoma, lung cancer
 

Alliance A071702: A phase II study of checkpoint blockade immunotherapy in patients with somatically hypermutated recurrent glioblastoma

Overview: This phase II Alliance trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has recurred and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).

Study Chair: Gavin P Dunn, MD, Washington University School of Medicine in St. Louis | Study Co-Chairs: Eva Galanis, MD, Mayo Clinic, and David Reardon, MD, Dana-Farber Cancer Institute | Activated: 10/30/2020 | CT.gov Link: http://bit.ly/AllianceA071702


Alliance A171901: Older non-small cell lung cancer patients (>/= 70 years of age) treated with first-line MK-3475 (pembrolizumab) +/- chemotherapy (oncologist's/patient's choice)

Overview: This Alliance trial studies the side effects of pembrolizumab with or without chemotherapy in treating patients with stage IV non-small cell lung cancer that has come back (recurrent) and has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the tumor in older patients with non-small cell lung cancer.

Study Chair | Study Co-Chair: Aminah Jatoi, MD, Mayo Clinic and Melisa L. Wong, MD, MAS, Univerisity of California San Francisco | Activated: 10/01/2020  | CT.gov Link: http://bit.ly/Alliance-A171901

 

 

For other articles in this issue of the Alliance E-news Newsletter, see below: